Crescent Biopharma at Morgan Stanley conference: pipeline bets build

On September 14th, 2026, Crescent Biopharma (CBIO) addressed the Morgan Stanley 24th Annual Global Healthcare Conference to present its oncology strategy. At the heart of their approach is CR-001, a PD-1/VEGF bispecific, along with a growing portfolio of antibody-drug conjugates. Management highlighted a strong cash position, with $305 million in pro forma cash following a July capital raise, which extends the company's runway into the second half of 2028.

The shares climbed to $19.68, marking a 1.39% increase from the previous close of $19.41, although the stock remained unchanged in after-hours trading. CBIO is valued at $849.6 million and has delivered a 66% return year-to-date. However, investment analysis suggests the stock may be overvalued at its current price.

The company is building its business around CR-001 as a potential next-generation immuno-oncology backbone. Management expects the first major data set from the ASCEND trial in Q1 2027, followed by additional combination data in mid-2027 and early CR-002 data by year-end. Crescent is open to partnerships, royalty deals, and other funding structures, while maintaining control over key assets.

The lead asset, CR-001, is a PD-1/VEGF bispecific designed to compete with emerging dual-target immuno-oncology drugs. Management aims to match the functional, structural, and pharmacokinetic features of rival ivonescimab, as demonstrated in preclinical studies. Crescent's clinical study, ASCEND, a Phase I/II trial of CR-001, investigates the compound in eight tumor types, with a focus on first-line non-small cell lung cancer, monotherapy, and standard-of-care chemotherapy combinations.